Boswellin® (Standardized Boswellia — Sabinsa)

Boswellia serrata
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Boswellin® is a STANDARDIZED BOSWELLIA SERRATA GUM RESIN EXTRACT developed by Sabinsa — distinguished by patented standardization and clinical evidence. Multiple variants including Boswellin® Super (high AKBA), Boswellin® PS (curcumin-boswellia phytosome), Boswellin® CG (curry gum). Used for: joint health, anti-inflammatory support, musculoskeletal applications, and inflammatory bowel adjunct. One of the most-recognized boswellia branded ingredients globally.

Studied Dose Per Sabinsa product specification (typical 100-400 mg/day variants)
Active Compound Boswellic acids (variant-specific standardization including KBA, AKBA)

Benefits

Joint Health and Osteoarthritis Support

Boswellin demonstrated to support joint health and reduce OA symptoms; multiple clinical trials show improvements in WOMAC scores, joint mobility, and inflammatory markers.

Anti-Inflammatory via 5-LOX Inhibition

Boswellic acids inhibit 5-lipoxygenase (5-LOX) enzyme — produces inflammatory leukotrienes; mechanism distinct from NSAID COX inhibition.

Inflammatory Bowel Adjunct

Boswellia traditional and modern applications include IBD adjunct; some evidence for ulcerative colitis and Crohn's symptom support.

Multiple Standardized Variants

Sabinsa offers multiple Boswellin variants for different applications: standard Boswellin, Boswellin Super (high AKBA), Boswellin PS (Phytosome with curcumin), Boswellin CG.

Long Traditional Use

Boswellia (Indian frankincense) used for over 2,000 years in Ayurveda for joint and inflammatory conditions.

Patented Sabinsa Standardization

Sabinsa's patented standardization processes ensure consistent boswellic acid content and clinical reproducibility.

Mechanism of action

1

5-Lipoxygenase (5-LOX) Inhibition

Boswellic acids inhibit 5-LOX — enzyme producing leukotrienes (inflammatory mediators); distinguishes from NSAID COX-only inhibition; relevant for inflammatory conditions where leukotrienes are central.

2

AKBA (Acetyl-11-Keto-Beta-Boswellic Acid) — Most Active

AKBA is the most potent boswellic acid for 5-LOX inhibition; Boswellin Super has higher AKBA content (typically 20-30%) vs standard Boswellin.

3

Cathepsin G Inhibition

Boswellic acids inhibit cathepsin G protease — additional anti-inflammatory mechanism.

4

TNF-α and NF-κB Pathway Modulation

Reduces TNF-α and modulates NF-κB inflammatory signaling.

5

Cartilage Matrix Protection

Inhibits matrix metalloproteinases (MMPs) — relevant to joint protection.

Clinical trials

1
Boswellia for Osteoarthritis — Multiple Trials
PubMed

Multiple boswellia/AKBA RCTs in OA patients.

OA patients across studies.

Significant improvements in WOMAC scores, joint mobility, inflammation markers.

2
Boswellin Specific Studies — Sabinsa

Sabinsa clinical studies of Boswellin variants for joint and inflammatory applications.

Adults with joint or inflammatory concerns.

Joint comfort improvements; inflammatory marker reductions.

About this ingredient

About the active ingredient

BOSWELLIN® is a STANDARDIZED BOSWELLIA SERRATA GUM RESIN EXTRACT developed by SABINSA CORPORATION — among the most-recognized boswellia branded ingredients globally. BOSWELLIA SERRATA BACKGROUND: tree resin (also called 'Indian frankincense' or 'Salai Guggul'); used in AYURVEDA for over 2,000 years for joint health and inflammatory conditions. BOSWELLIC ACIDS: triterpene compounds; the active compounds; AKBA (acetyl-11-keto-beta-boswellic acid) is most potent for 5-LOX inhibition. SABINSA BOSWELLIN VARIANTS: (1) BOSWELLIN® standard — 65% boswellic acids; (2) BOSWELLIN® SUPER — high AKBA (20-30%); (3) BOSWELLIN® PS — curcumin-boswellia phytosome combination; (4) BOSWELLIN® CG — curry gum variant.

KEY DISTINCTIONS: (1) PATENTED Sabinsa standardization; (2) MULTIPLE VARIANTS for different applications; (3) Long clinical research history; (4) Self-affirmed GRAS; (5) Among Sabinsa's flagship ingredients.

EVIDENCE-BASED USES: (1) Joint health and OA support; (2) Anti-inflammatory via 5-LOX inhibition; (3) IBD adjunct (some evidence); (4) Sports recovery; (5) Inflammatory conditions.

CRITICAL CAUTIONS: (1) PREGNANCY — limited safety data; AVOID; (2) PRE-SURGERY — discontinue 1-2 weeks before; (3) ANTICOAGULANTS — modest effects; (4) DOSE — 100-400 mg/day variants; per Sabinsa specification; (5) DURATION — joint effects build over 4-12 weeks; (6) BOSWELLIN vs CASPEROME (Indena) — different standardization approaches; Boswellin offers AKBA-emphasized variants; Casperome offers Phytosome bioavailability + full-spectrum 11 boswellic acids; both have evidence; (7) FOR JOINT HEALTH — comprehensive approach: exercise, weight management, possibly NSAIDs when warranted, multiple natural options; (8) AKBA-FOCUSED vs FULL-SPECTRUM — Boswellin Super emphasizes potent AKBA; some evidence full-spectrum better matches natural resin activity; both work; (9) BOSWELLIA + CURCUMIN COMBINATION — Boswellin PS combines both; common synergistic combination for joint health; (10) BRAND VERIFICATION — Boswellin® is Sabinsa trademark; specific patented standardization; clinical evidence on this branded form; (11) Among the most evidence-based boswellia ingredients with extensive Sabinsa research.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress.
Allergic reactions rare.
Skin rash rare.

Important Drug interactions

ANTICOAGULANTS — modest antiplatelet effects.
5-LOX inhibitors (zileuton) — same mechanism; theoretical additive.
Anti-inflammatory medications — generally complementary.
Pregnancy — limited safety data; AVOID.
Lactation — limited data.
Pre-surgery — discontinue 1-2 weeks before.

Frequently asked questions about Boswellin® (Standardized Boswellia — Sabinsa)

What is the recommended dosage of Boswellin® (Standardized Boswellia — Sabinsa)?

The clinically studied dose for Boswellin® (Standardized Boswellia — Sabinsa) is Per Sabinsa product specification (typical 100-400 mg/day variants). Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Boswellin® (Standardized Boswellia — Sabinsa) used for?

Boswellin® (Standardized Boswellia — Sabinsa) is studied for joint health and osteoarthritis support, anti-inflammatory via 5-lox inhibition, inflammatory bowel adjunct. Boswellin demonstrated to support joint health and reduce OA symptoms; multiple clinical trials show improvements in WOMAC scores, joint mobility, and inflammatory markers.

Are there side effects from taking Boswellin® (Standardized Boswellia — Sabinsa)?

Reported potential side effects may include: Generally well-tolerated. Mild GI distress. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Boswellin® (Standardized Boswellia — Sabinsa) interact with medications?

Known drug interactions may include: ANTICOAGULANTS — modest antiplatelet effects. 5-LOX inhibitors (zileuton) — same mechanism; theoretical additive. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Boswellin® (Standardized Boswellia — Sabinsa) good for joint health?

Yes, Boswellin® (Standardized Boswellia — Sabinsa) is researched for Joint Health support. Boswellin demonstrated to support joint health and reduce OA symptoms; multiple clinical trials show improvements in WOMAC scores, joint mobility, and inflammatory markers.